Sakata Yoshihiko, Kawamura Kodai, Ichikado Kazuya, Suga Moritaka, Yoshioka Masakazu
Division of Respiratory Medicine, Saiseikai Kumamoto Hospital, 5-3-1 Chikami, Kumamoto 861-4193, Japan.
Respir Med Case Rep. 2013 Jun 3;9:38-41. doi: 10.1016/j.rmcr.2013.04.002. eCollection 2013.
Hermansky-Pudlak syndrome (HPS) is an autosomal recessive disorder characterized by oculocutaneous albinism, bleeding tendency, and lysosomal accumulation of ceroid-like material, with occasional development of interstitial pneumonia (IP). Nine genetically distinct subtypes of HPS are known in humans; IP develops primarily in types 1 and 4. Most reported cases of HPS with IP are type 1, and there are no published reports of type 4 in Japanese individuals. A 58-year-old man with congenital oculocutaneous albinism and progressive dyspnea for 1 month was admitted to our hospital. We administered high-dose corticosteroids on the basis of a diagnosis of acute exacerbation of interstitial pneumonia. Respiratory symptoms and the findings of high-resolution computed tomography (CT) showed improvement. He was diagnosed with HPS type 4 with interstitial pneumonia on the basis of gene analysis. He has been receiving pirfenidone for 1 year and his condition is stable. This is the first report on the use of pirfenidone for HPS with IP caused by a novel mutation in the HPS4 gene. We conclude that HPS should be suspected in patients with albinism and interstitial pneumonia. High-dose corticosteroid treatment may be useful in cases of acute exacerbation of interstitial pneumonia due to HPS-4, and pirfenidone may be useful and well tolerated in patients with HPS-4.
赫尔曼斯基-普德拉克综合征(HPS)是一种常染色体隐性疾病,其特征为眼皮肤白化病、出血倾向以及类蜡样物质的溶酶体积聚,偶尔会发展为间质性肺炎(IP)。人类已知有9种基因不同的HPS亚型;IP主要在1型和4型中发生。大多数报告的伴有IP的HPS病例为1型,且在日本人群中尚无4型的公开报告。一名58岁男性,患有先天性眼皮肤白化病,渐进性呼吸困难1个月,入住我院。基于间质性肺炎急性加重的诊断,我们给予了大剂量皮质类固醇治疗。呼吸症状及高分辨率计算机断层扫描(CT)结果显示有所改善。经基因分析,他被诊断为患有伴有间质性肺炎的4型HPS。他接受吡非尼酮治疗已1年,病情稳定。这是关于使用吡非尼酮治疗由HPS4基因新突变引起的伴有IP的HPS的首例报告。我们得出结论,对白化病和间质性肺炎患者应怀疑患有HPS。大剂量皮质类固醇治疗对于因HPS-4导致的间质性肺炎急性加重可能有效,且吡非尼酮对于HPS-4患者可能有效且耐受性良好。